Allogeneic Stem Cell Transplantation Following Chemotherapy in Patients With Hemoglobinopathies
Status:
Completed
Trial end date:
2009-07-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to determine if treatment with reduced-dose busulfex,
fludarabine and alemtuzumab (CAMPATH) followed by sten cell infusion will allow for donor
stem cells to grow in patients with hemoglobinopathies bone marrow and restore circulating
blood counts. In addition the incidence and severity of side effects and of graft vs. host
disease (GVHD) will be monitored.
Phase:
Phase 2
Details
Lead Sponsor:
Dana-Farber Cancer Institute
Collaborators:
Beth Israel Deaconess Medical Center Brigham and Women's Hospital Emory University Feist-Weiller Cancer Center at Louisiana State University Health Sciences Massachusetts General Hospital Ohio State University